Meeting
2017 Gastrointestinal Cancers Symposium
5-fluorouracil, oxaliplatin and dasatinib (FOLFOX-D) for previously untreated metastatic pancreatic adenocarcinoma.
Authors
Thomas J. George Jr.
University of Florida, Gainesville, FL
Thomas J. George Jr., Long H. Dang , Karen Colleen Daily , Jason Scott Starr , Hiral D. Parekh , Alison Marguerite Ivey , Daniel Delitto , Carmen Joseph Allegra , Steven J. Hughes , Xiaomin Lu , Margaret A. McEwan , Jessica L Cioffi , Jose Gilberto Trevino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01652976
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract TPS517)
DOI
10.1200/JCO.2017.35.4_suppl.TPS517
Abstract #
TPS517
Poster Bd #
O13
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Final results from a phase II study of 5-fluorouracil, oxaliplatin, and dasatinib (FOLFOX-D) in previously untreated metastatic pancreatic adenocarcinoma.
First Author: Thomas J. George Jr.
Poster
2018 Gastrointestinal Cancers Symposium
Final toxicity results from a phase II study of 5-fluorouracil, oxaliplatin, and dasatinib (FOLFOX-D) in previously untreated metastatic pancreatic adenocarcinoma.
First Author: Thomas J. George Jr.
Poster
2014 Gastrointestinal Cancers Symposium
Src inhibition through a phase II study of 5-fluorouracil, oxaliplatin, plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma.
First Author: Thomas J. George
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TnT) with FOLFOX followed by short course radiation in locally advanced rectal cancer: A phase II study.
First Author: Janice Zhao